chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My symptoms included fever with night sweats, pain in my head, sinus infection, productive phlegm, tingling in my hands and legs and muscle pains. My temperature went from 98 to 92 one day. I tested negative for the first two days at home for COVID-19. At the doctor I took a PCR, and it was negative. The next day I tested positive. I began to take Paxlovid and began to feel better. When the Paxlovid ended, two days later I got a rebound case. This time I could not smell, or taste and I was sick for another 4-five days. My temperature did the same thing. I had sinus issues, and my ear was clogged. I still have an ear infection and will see an ENT later this week.
Both feet have been numb since around Sept 15th 2021.  Doctor has prescribed a supplement called EB-N5DR.  Been taking it twice a day since 1/29/2022.  So far, no benefits observed.
Pt. developed cellulitis in right arm after receiving the flu vaccine and PNEUMOVAX.
Painful lymphadenopathy in L axilla; Difficult to sleep.; dose number: 3; dose number: 3 (booster); This is a spontaneous report from a contactable other hcp (patient). A 46-years-old (nonpregnant) female patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Lot Number was 301558A, Expiration Date: Unknown) as dose 3 (booster), single intramuscular, administered in Arm Left on 29Sep2021 12:30 (age at vaccination 46 years) for covid-19 immunisation. Medical history included epilepsy from an unknown date and unknown if ongoing. Concomitant medication in two weeks included keppra taken for an unspecified indication, start and stop date were not reported. No covid prior to vaccination. No known allergies were reported. Historical vaccines received were (BNT162B2, Formulation: Solution for injection, Lot Number was EL0142, Expiration Date: Unknown) as dose 1, single intramuscular, administered in Arm Left on 04Jan2021 for covid-19 immunisation and (BNT162B2, Formulation: Solution for injection, Lot Number was EL9261, Expiration Date: Unknown) as dose 2, single intramuscular, administered in Arm Left on 25Jan2021 for covid-19 immunisation. No other vaccine in four weeks was reported. On 30Sep2021 10:00pm the patient experienced Painful lymphadenopathy in L axilla about 36 hours after dose 3. Lasted for 3 days, difficult to sleep. On 04Oct2021 the patient underwent lab tests and procedures which included (Nasal Swab) sars-cov-2 test: negative. No treatment received. The outcome of events Painful lymphadenopathy in L axilla about 36 hours after dose 3. Lasted for 3 days. Difficult to sleep was recovered on 04Oct2021.  Follow-up attempts are completed. No further information is expected.
Redness/swelling at injection site approx 10 cm across. Recommend ice pack to affected area.
Arm still sore,.   dizzy,    feet and ankles swollen, stomach hurts,   all my muscles hurt,.  headache,. nausea,. feel tired no energy
Information had been received from a healthcare worker who reported that a 65 year old female with codeine allergy received a dose of PNEUMOVAX 23 (lot# K007826, expiration date 03-FEB-2016) in an unspecified arm on 24-NOV-2014. Concomitant medication included alendronate (manufacturer not specified), DIFLUCAN, estradiol, fenofibrate, PRILOSEC, WELLBUTRIN and ZOVIRAX. On 25-NOV-2014, the patient developed a high fever, nausea and stated that her arm hurts. Patient called into the office to report her symptoms but was not seen in the office. Symptoms were treated with BENADRYL and an unspecified topical biofreeze spray. It was reported that patient recoverd on 29-NOV-2014. Two additional AE cases were reported related to this same PNEUMOVAX 23 lot; Lot# K007826 exp. 03-FEB-2016 (See SR#'s 1-12956467246 and 1-12956447566). Lot check requested, please provide these results to the physician. No further information provided. Additional information has been requested.
This spontaneous report has been received from a 68 year old female patient via the agency referring to herself who was with chronic obstructive pulmonary disease. On an unknown date the patient was vaccinated with PNEUMOVAX 23 (dose, route and lot# not reported). On an unknown date the patient experienced pain/soreness at injection site pain and sore arm. The events diminished after stopping suspected therapy. Therapy with PNEUMOVAX 23 was restarted and injection site pain and pain in extremity did not recur. The patient was concerning at the site pain and put a little ice on it. The outcome of the patient was unknown. It was unspecified if the patient sought medical attention. The reporter considered injection site pain and pain in extremity to be related to PNEUMOVAX 23. Additional information has been requested.
Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Error: Wrong Dose of Vaccine - Too Low-, Additional Details: First dose administered was just air and immunizer then informed m,other she was going to issue vaccine the vaccine. Patient was injected with air on first injection and then given correct dose of vaccine.
Red  rash at injection site appearing 6 days after vaccination. Itchy. No swelling.
pain in calf; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (pain in calf) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In February 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (pain in calf). At the time of the report, PAIN IN EXTREMITY (pain in calf) outcome was unknown.            No concomitant medications were provided. No treatment medications were provided.
Redness, pain, swelling 3 days after vaccine administered on (R) deltoid 6 days after vaccine administered 102 fever, documented today. Nausea and headache. Treated for possible cellulitis. KEFLEX 500 TID x 10 days; ibuprofen.
A report has been received from a Physician concerning a 14 year old, female subject, who had been receiving FLUMIST QUADRIVALENT (intranasal). FLUMIST QUADRIVALENT (intranasal) started on an unknown date. It was reported that the patient was administered expired FLUMIST QUADRIVALENT on 08-Sep-2014. The outcome of the event of administered expired FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious.
Onset of joint pain 2 days after vaccination. This has continued for 10 days so far
The minute the injecter shot my left arm with the vaccine I felt an intense pain, unlike any pain I've felt with previous vaccinations. After he removed the needle, I was bleeding quite a lot.  Since that day, which has been over a month now, I have felt intermittant burning and stinging sensations with pain that radiates down my arm to my fingers.
Day 8 post injection developed pain, redness, swelling, hot to touch, itchiness at injection site.  Symptoms developed this morning, so of unknown duration.  Still experiencing symptoms.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant medications were not reported. The nurse reported that on 02-JUL-2015, the patient was vaccinated with improperly stored RECOMBIVAX HB lot # K009953, expiry date 03-APR-2016 (dose and route of administration unspecified). No adverse symptoms were reported. This is one of several reports received from the same reporter. Additional information has been requested
Hoarse voice, stuffy nose, nasal drainage in back of throat, occasional cough, foggy brain, migraine, fatigue, muscle aches. Treatment at home: Lots of liquids & rest. Although vaccine was administered at the pharmacy  will schedule Dr. Appt with primary physician as referred to by pharmacy. Outcome: To be determined
Erythema multiforme. A physician reported the occurrence of erythema multiforme in a 45 year old female who was vaccinated with hepatitis A vaccine inactivated (Havrix) for prophylaxis. The subject's medical history included allergy to sulfamethoxazole/ trimethoprim (Bactrim). The subject had no known allergy to yeast or to other inactive ingredients in Havrix. Concurrent medications included amitriptyline, nifedipine (Procardia XL), and hydrochlorothiazide. The subject had been taking hydrochlorothiazide for "years" prior to immunization. On 03 April 2003, the subject received her first injection of Havrix. On 07 April 2003, the subject received her first injection of Havrix. On 07 April 2003, four days post-immunization, the subject noticed that she had developed a rash. On 08 April 2003, the subject was seen by the physician, who observed a "mild and fairly widespread" rash on the subject's forearms and lower legs. The physician made a diagnosis of erythema multiforme. No biopsy was performed and no treatment was provided. The reporting physician considered the erythema multiforme to be possibly related to Havrix administration. The reporting physician stated that the erythema multiforme could also have been associated with viral illness although, there was "no other evidence of such", or an adverse reaction to hydrochlorothiazide. The Havrix immunization series was discontinued. The most recent information, received on 24 April 2003, indicated that the erythema multiforme persisted as of 21 April 2003. The physician considered the event to be nonserious; however, erythema multiforme is considered GSK medically serioius.
Doses administered from vial with affected temperature excursion; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered from vial with affected temperature excursion) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered from vial with affected temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered from vial with affected temperature excursion) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided.  Reporter states that 2,340 doses experienced temperature excursion intended to be stored in freezer.
Provider summary "This is a 67 y/o female with a past medical history significant for advanced MS who presented to the ED on 6/9/2022 for evaluation of acute weakness and dyspnea following exposure to her daughter who had tested positive for COVID.  She was found to be hypoxic in the ED.  The patient was admitted to the hospitalist service for COVID pneumonia with hypoxia. She had an uneventful hospitalization and when medically stable, the patient was discharged to Lakeland Health Watervliet for  acute inpatient rehabilitation of functional and cognitive deficits.   Symptoms related to these abovementioned conditions and events were well-controlled, and the patient was discharged medically stable and improved. There were no significant acute episodes that affected length of stay or tolerance to therapies.  Patient was noted to have elevated blood sugars and leukocytosis while on dexamethasone.  Blood sugars and WBCs improved when steroid course was completed, though blood sugars did not completely return to normal despite use of home glimepiride requiring continued use of Lantus and ISS.  Lantus was discontinued and patient started on Januvia in conjunction with home glimeperide.  Blood sugars appear to be well controlled.     The patient was also provided orthotics / durable medical equipment to ensure improved function and safety in the rehabilitation and home setting.   Occupational, Physical and Speech Language Pathology therapists and a Neuropsychologist were consulted for evaluation and treatment so as to best determine the amount and extent of services required for cognitive and functional optimization. The patient received a minimum of 180 minutes of therapy per day for 5 out of 7 days, or more than 15 hours of intensive therapy over the course of a week.    While in the unit, the acute rehabilitation service also held interdisciplinary team conferences on a weekly basis to establish specific short- and long-term goals during rehabilitation, and for discharge. Barriers to discharge were also noted and updated as they were addressed. Plans to assure continuity and coordination of care after discharge from the acute rehabilitation unit were also established and explained to the patient and care provider(s).   While on the unit, the patient was monitored on a daily basis by a physician who evaluated and managed co-morbidities and medical conditions, as necessary.  Noteworthy events related to the patient's rehabilitative stay included the below mentioned - which were treated as indicated."
Dyspnea secondary to PE.  Treatment is full anticoagulation. Outcome is undetermined, since patient is still in the hospital.
Bells Palsy; This is a spontaneous report. A contactable consumer (patient) reported that a 64-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number unknown, expiration date unknown), via an unspecified route of administration, administered in right arm on 27Feb2021 at 10:45 AM at the age of 64 years old at a single dose for COVID-19 immunisation. Medical history included diabetes, prior heart attack and allergies: codeine, penicillin. Concomitant medications included metoprolol, pravastatin, metformin, valsartan and clofarabine. Patient didnot receive any other vaccines within 4 weeks prior to the COVID vaccine. On 22Mar2021 at 09:30 AM, the patient experienced bells palsy. Adverse event resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Adverse event treatment: CT scan, neuro evaluation, eye exam and steroids. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient had not yet recovered from the event.  Information on the lot/batch number has been requested.
PATIENT FELT FLU-LIKE SYMPTOMS OF FEVER, SWEATING AND MUSCLE ACHES. HE ALSO EXPERIENCED INJECTION-SITE PAIN AND REDNESS.
tachycardia, arm pain, erythema, swelling; facial flushing/burning; fatigue, rash On 1-14-21 she tested +for Covid
I tested positive for COVID-19 after vaccination; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (I tested positive for COVID-19 after vaccination) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (I tested positive for COVID-19 after vaccination). At the time of the report, COVID-19 (I tested positive for COVID-19 after vaccination) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided Treatment medications were not provided
burning & flushing @ time of inj;fever which started p/shot;stayed in bed 5 days;nausea;day 10 rash on body began on neck& spread to torso; 2 1/2 wk p/shot began having fever, sore throat & rash;cont w/aching, sore throat, h/a, fever;
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 23-AUG-2011, the patient was inoculated with ZOSTAVAX at a pharmacy as recommended for routine adult health maintenance for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. On or about 30-NOV-2011, the patient was treated by a physician for a blistering vesicular outbreak, that was diagnosed as severe herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
Information has been received from a nurse practitioner concerning a 12 month old Asian male pt with probably Still's disease who on 11/30/01 was vaccinated with the first dose of MMR II (lot 639514/0601L) (left SC). There was no noted adverse events following prior vaccinations. On 12/08/01 the child developed a severe "measles rash." The rash was described as being macular/papular and very red. It was also reported that some of the rash was raised and there was some "halos." The child also developed a high fever with temperatures up to 103 F for two days. The child was seen on 12/10/01 and was diagnosed with bilateral otitis media and rash status post immunization. The child subsequently recovered from the events. No further info is expected. The nurse practitioner also reported that a 15 month old child developed a morbilliform rash following vaccination with MMR II (lot 640962/1095L) (see WAES0112USA01480).
Exstream high Blood pressure for about a month.  Danger of stroke.  Increased blood pressure medicine.  Still on medicine.
Immediately after vaccination, Patient became quiet and seemed a little disoriented and surprised by the vaccination process. We asked him how he was doing, and he said he was feeling okay. However we asked him to sit for a few minutes after vaccination. After that, upon standing, he said is head felt a little dizzy. He was asked to sit back down.  He appeared a little sweaty as well and  reported that his stomach felt a little unsettled. He was given an ice pack for the back of his neck, water, apple juice, and popcorn and was monitored for 20 additional minutes. He never lost consciousness but seemed to have a minor vasovagal response. He was able to stand without feeling dizzy prior to leaving our office. He left with this mom and siblings.
Around December 20th I started feeling like my left side of my chest was irritated- thinking maybe we had changed laundry detergent. We had not changed anything but I still had this feeling of tingling and that something was off. This continued until around from my chest to my sternum and around to my spine. About Jan 6th 2022 the rash developed and that led me to go to urgent care. It turned out that I had shingles- and I was able to get treatment. I have recovered but this lasted for about 8 weeks, but I do have some scarring from the rash.
Had onset of extreme fatigue, slept for 4 hours in the afternoon, returned to bed and slept for another 15 hours. Noted redness, swelling and warmth on arm where vaccine given which also covered her left chest and around to her left shoulder blade. Had these sypmtoms for 2-3 days with them subsiding slowing. Saw physician 3 days later.
Patient collapsed and could not be revived. There was no prior warning. She was otherwise in good condition for her age. The death was listed as probable cardiac arrest but no autopsy was performed. Since it occurred so close to the vaccine shot I thought someone may want to know.
Left arm pain, swelling, redness at site lightheadedness, nausea. VS: 108/78 BP - 104 HR - 18 R Pulse O - 87! P 96 (standing) T 97.8. Exam - local redness, abdomen NT, lungs clear left arm swelling at site.
Patient received the vaccination at 1148. A few minutes after receiving the vaccine the patient became faint. The patient was placed in Trendelenburg, drank juice and remained laying for 20 minutes. VSS at 1103 when patient sat up. Patient did experience dizziness or blurred vision upon sitting upright. After sitting for several minutes his blood pressure was 100/59.
Fever (102) , Chills, Headache 24 hours after injection. They lasted about 24 hours and then started feeling better. Also had soreness at injection site that began when I received my shot and lasted about 3 days.
A report has been received from a Health Professional concerning a patient, female subject, who had been receiving Nasal FLUMIST QUADRIVALENT. FLUMIST QUADRIVALENT (Intranasal) started on an unknown date. The reporter stated inadvertently expired FLUMIST QUADRIVALENT administered. The outcome of the event of expired FLUMIST QUADRIVALENT administered is unknown. The report was considered to be non-serious by the reporter.
blocked salivary gland; "hay fever type of response"; sniffling off and on; burning sensation in both legs; A spontaneous report was received from a consumer concerning herself, 78 years old, female patient who developed blocked salivary gland/salivary gland disorder, burning sensation in both legs/burning sensation, "hay fever type of response"/seasonal allergy, sniffling off and on/rhinorrhoea.  The patient's medical history included blocked salivary glands.  Products known to have been used by the patient, within two weeks prior to the event, included Hydrochlorothiazide, Valsartan.  The patient received their first of two planned doses of mRNA-1273 (Batch number: 030M20A) on  11 Feb 2021 intramuscularly at unknown injection site for prophylaxis of COVID-19 infection.    On 11 Feb 2021 the patient experienced burning sensation in both legs (from ankles to above knees) that resolved the next day. On 12 Feb 2021, she also reported hay fever type of response with sniffling that was on and off. On 27 Feb 2021, she reported a blocked salivary gland. Treatment of the events included amoxicillin and clavulanate potassium and prednisone.    Action taken with mRNA-1273 in response to the event was not provided.  The event burning sensation in both legs was considered resolved. The outcome of the events blocked salivary gland, hay fever type of response, sniffling off and on was not reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.